PEFICITINIB: A PROMISING SOLUTION FOR RA JOINT DISEASE?

Peficitinib, a investigational compound targeting the spleen tyrosine kinase pathway , offers a significant step in the approach of inflammatory joint conditions. Initial research data suggest that it appears to demonstrably alleviate swelling and enhance physical capabilities in patients who are